关于"SR604 注射液"新增适应症获得药物临床试验批准通 知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的关于 SR604 注射液新增用于 血管性血友病患者出血发作的预防治疗的《药物临床试验批准通知书》（受理号： 【CXSL2500733】，通知书编号：2025LP02910）。现将相关情况公告如下： 证券代码：002252 证券简称：上海莱士 公告编号：2025-073 上海莱士血液制品股份有限公司 一、 《药物临床试验批准通知书》的主要情况 药物名称：SR604 注射液 药品注册分类：治疗用生物制品 1 类 适应症：血管性血友病患者出血发作的预防治疗 申请事项：境内生产药品注册临床试验 申请人：上海莱士血液制品股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 22 日受理的 SR604 注射液临床试验申请符合药品注册的有关要求，同意 本品开展血管性血友病患者出血发作的预防治疗的临床试 ...

Core Viewpoint - The article highlights the latest holdings of securities firms in the A-share market as of the end of Q3 2025, indicating significant investment activity and sector preferences among these firms [1][5]. Holdings Overview - As of the end of Q3 2025, 44 securities firms appeared in the top ten shareholders of 361 listed companies, with a total holding value of 66.623 billion yuan [1]. - The most concentrated sectors for securities firm investments are hardware equipment and chemical industries, with 41 and 33 stocks respectively, followed by pharmaceuticals and machinery with 26 and 20 stocks [1]. Major Holdings - The top holdings by securities firms include: - CITIC Securities holds 1.3743 million shares of Muyuan Foods valued at 1.984 billion yuan [4]. - Shenwan Hongyuan has a holding of 1.2148 million shares of Guangqi Technology valued at 1.079 billion yuan [4]. - Other notable holdings include Cangge Mining and Jilin Aodong, with holdings valued at 928 million yuan and 865 million yuan respectively [2][4]. New Investments - In Q3, securities firms entered the top ten shareholders of 206 new stocks, primarily in the non-ferrous metals, pharmaceuticals, hardware equipment, and chemical sectors [5]. - Noteworthy new investments include: - Guotai Junan's entry into Postal Savings Bank with a holding valued at 727 million yuan [5]. - CITIC Securities' new position in Huayuan Ecology valued at 344 million yuan [5]. Increased Holdings - A total of 63 stocks saw increased holdings from securities firms in Q3, with significant increases in positions such as: - Dongfang Securities increased its holding in Inner Mongolia Huadian by 21.94 million shares, adding over 8.8 million yuan in value [5]. - CITIC Securities increased its position in Muyuan Foods by 507,500 shares, adding approximately 433 million yuan [5]. Decreased Holdings - Some securities firms reduced their holdings in certain stocks, such as CITIC Securities reducing its position in Xin Nuo Wei, while others like Shenwan Hongyuan reduced holdings in Guangqi Technology and Cangge Mining but saw their holding values increase due to stock price appreciation [6]. Self-operated Business Performance - The performance of securities firms' self-operated businesses is closely linked to their stock holdings, with total self-operated income reaching 186.857 billion yuan in the first three quarters of the year, accounting for over 44% of total revenue [7]. - CITIC Securities led with a self-operated income of 31.603 billion yuan, a year-on-year increase of approximately 46% [8]. Self-operated Business Breakdown - The self-operated income of major securities firms for the first three quarters includes: - CITIC Securities: 31.603 billion yuan, 45.88% year-on-year growth [8]. - Guotai Junan: 20.37 billion yuan, 90.11% year-on-year growth [8]. - Other firms like China Galaxy and Shenwan Hongyuan also reported significant self-operated income exceeding 10 billion yuan [8].

Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. announced the completion of a share buyback plan by certain directors and senior management, reflecting their confidence in the company's strategic development and long-term investment value [3][10]. Summary by Sections Share Buyback Plan - The company disclosed a plan for certain directors and senior management to increase their shareholdings starting from September 5, 2025, for a period of six months, with a minimum investment of RMB 6 million [3][10]. - The buyback was executed through centralized bidding, resulting in the acquisition of 946,000 shares, representing 0.014% of the total share capital, with a total expenditure of RMB 6.4828 million [10]. Participants in the Buyback - The buyback involved key executives including Jun Xu, Shen Jihui, Lu Hui, Liu Zheng, Song Zhengmin, Chen Leqi, and Huang Qinbing [3][10]. - Prior to the buyback, these executives held shares under the first employee stock ownership plan, with specific unblocked shares awaiting conditions for release [4]. Purpose and Conditions - The buyback aims to enhance investor confidence and is based on the executives' strong belief in the company's strategic direction [6][10]. - There is no set price range for the buyback; the executives will determine the timing based on their assessment of the stock's value [6][10]. Compliance and Regulations - The buyback adheres to relevant laws and regulations, ensuring that it does not affect the company's share distribution or control [10]. - The participating executives committed to not selling their shares during the lock-up period following the buyback [9][10].

Core Points - Shanghai Laishi announced that from September 10, 2025, to October 30, 2025, some directors and all senior management personnel cumulatively increased their holdings of the company's shares by 946,000 shares, accounting for 0.014% of the total share capital [2] - The total amount of the increase in shareholding was 6.4828 million yuan, and this shareholding increase plan has been completed [2]

证券代码：002252 证券简称：上海莱士 公告编号：2025-072 上海莱士血液制品股份有限公司 关于公司部分董事及全体高级管理人员增持股份计划 实施完成的公告 信息披露义务人公司副董事长兼总经理Jun Xu（徐俊）先生、副总经理沈 积慧先生、副总经理陆晖先生、副总经理兼董事会秘书刘峥先生、副总经理宋 正敏女士、财务负责人陈乐奇先生、副总经理黄勤兵先生保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、上海莱士血液制品股份有限公司（"公司"）于2025年9月5日披露了《关 于公司部分董事及全体高级管理人员增持股份计划的公告》（公告编号：2025- 062），公司部分董事及全体高级管理人员出于对公司拓浆脱浆战略发展规划的 坚定信心及长期投资价值的充分认可，结合当前资本市场形势，为进一步增强 投资者信心，计划自2025年9月5日起6个月内（除法律、法规及深圳证券交易所 业务规则等有关规定不准增持公司股票的期间之外）以自筹资金方式增持公司 股份，拟合计增持金额不低于人民币600万元。 2、增持计划 ...

Core Viewpoint - Shanghai Laishi (002252.SZ) announced that from September 10, 2025, to October 30, 2025, certain directors and all senior management personnel cumulatively increased their holdings of the company's shares by 946,000 shares, accounting for 0.014% of the total share capital, with a total investment amount of 6.4828 million yuan. The share buyback plan has been completed [1] Summary by Category - **Shareholding Increase** - The company’s directors and senior management increased their shareholdings by 946,000 shares [1] - This increase represents 0.014% of the total share capital [1] - The total amount invested in this share buyback was 6.4828 million yuan [1] - **Completion of Buyback Plan** - The share buyback plan has been successfully completed [1]

Core Viewpoint - Shanghai Laishi is a leading domestic blood product company with strong revenue and profit performance, but faces challenges in gross margin and profitability [2][3][6]. Group 1: Company Overview - Shanghai Laishi was established on October 29, 1988, and listed on the Shenzhen Stock Exchange on June 23, 2008, with its headquarters in Shanghai [1]. - The company specializes in the production and sale of blood products and has a comprehensive production base and numerous plasma collection stations, leading in plasma collection volume in China [1]. Group 2: Financial Performance - In Q3 2025, Shanghai Laishi achieved a revenue of 6.091 billion yuan, ranking first among seven companies in the industry, with the second company, Tiantan Biological, at 4.465 billion yuan [2]. - The net profit for the same period was 1.47 billion yuan, also the highest in the industry, with Tiantan Biological at 1.12 billion yuan [2]. - Revenue decreased by 3.54% year-on-year, while net profit decreased by 19.97% year-on-year [5]. Group 3: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 14.30%, significantly lower than the industry average of 28.01%, indicating strong solvency [3]. - The gross margin for Q3 2025 was 37.12%, down from 40.64% in the previous year and below the industry average of 44.76%, suggesting a need for improvement in profitability [3]. Group 4: Management and Shareholder Information - The controlling shareholder is Haiyingkang (Qingdao) Medical Technology Co., Ltd., with Haier Group as the actual controller [4]. - The chairman, Tan Lixia, holds multiple positions, including Vice Chairman of Haier Group, while the general manager, Xu Jun, saw a salary increase to 8.0964 million yuan in 2024 from 6.5069 million yuan in 2023 [4]. Group 5: Market Position and Future Outlook - The company has a strong competitive position in blood products, with six major production bases and 55 plasma collection stations, and a nearly 12% year-on-year increase in plasma collection volume in H1 2025 [6]. - The acquisition of Nanyue Biological in June 2025 is expected to enhance scale and coverage [6]. - The product SR604 is currently in Phase IIb clinical trials, with projected net profits for 2025-2027 estimated at 1.95 billion, 2.32 billion, and 2.65 billion yuan, respectively [6].

Group 1 - The company Shanghai Laishi announced that its Vice Chairman and General Manager Xu Jun, along with several directors and all senior management, collectively increased their shareholding by 946,000 shares from September 10 to October 30, 2025, accounting for 0.014% of the company's total share capital [1] - The total amount invested in this share buyback was 6.4828 million yuan, which was completed ahead of the original plan [1] - The initial plan was set to start on September 5, 2025, with a duration of six months and a minimum investment amount of 6 million yuan [1]

Core Viewpoint - Shanghai Laishi (002252) demonstrates strong operational resilience and growth potential in a complex market environment, as evidenced by its third-quarter report for 2025, which highlights significant improvements in cash flow and ongoing business expansion [1] Financial Performance - The company achieved operating revenue of 2.139 billion yuan, maintaining a steady performance [1] - Net cash flow from operating activities increased significantly by 33.99%, reaching 691 million yuan, reflecting excellent working capital management efficiency [1] Business Development - The company completed the acquisition of Commodity Biology, resulting in a steady growth of asset scale to 38.020 billion yuan, laying a solid foundation for long-term development [1] - In the field of innovation and research, the core product "SR604 injection" has successfully progressed to the IIb clinical trial phase, and a new application for the indication of vascular hemophilia has been accepted, enriching the product pipeline and indicating promising future market potential [1] Management Confidence - The management team and controlling shareholder express strong confidence in the future, with the controlling shareholder, Haiyingkang, implementing three rounds of share buybacks this year, totaling nearly 1.5 billion yuan [1] - The company has also actively promoted share repurchases, with a total repurchase amount of 470 million yuan by the end of the reporting period, aimed at future employee incentives [1] - These initiatives not only reflect internal recognition of the company's intrinsic value but also effectively boost market confidence, positioning Shanghai Laishi for high-quality growth [1]

Group 1 - The company Shanghai Laishi reported that as of October 20, 2025, the total number of shareholders is 110,595 [2]